United Kingdom (GB)

The attitudes of medical students in Europe toward the clinical importance of histology (2017) Moxham BJ, Emmanouil-Nikoloussi E, Brenner E, Plaisant O, Brichova H, Kucera T, Pais D, et al. Journal article VEGF as a Paracrine Regulator of Conventional Outflow Facility (2017) Reina-Torres E, Wen JC, Liu KC, Li G, Sherwood JM, Chang JYH, Challa P, et al. Journal article Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma (2017) O'Callaghan J, Crosbie DE, Cassidy PS, Sherwood JM, Flügel-Koch C, Lütjen-Drecoll E, Humphries MM, et al. Journal article Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study (2017) Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, et al. Journal article Genetic variation of PNPLA3 and TM6SF2 associate with hepatocellular carcinoma in patients with alcohol-related cirrhosis (2017) Stickel F, Buch S, Janet F, Rosendahl J, Morgan MY, Nischalke HD, Lammert F, et al. Conference contribution Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome (2017) Pavel ME, Gable J, Kulke MH, Bergsland E, Anthony LB, Caplin ME, Oberg KE, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension (2017) Cwikla JB, Wolin EM, Pavel ME, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution "AND SUDDENLY YOU ARE A PERSON AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS!" DIFFERENT PERSPECTIVES OF INDIVIDUALS ON PREDICTIVE TESTING - RESULTS OF AN INTERNATIONAL QUALITATIVE INTERVIEW STUDY (2017) Mosor E, Stoffer M, Steiner G, Raza K, Stack RJ, Simons G, Falahee M, et al. Conference contribution SECUKINUMAB PROVIDES RAPID AND SUSTAINED PAIN RELIEF IN PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE FUTURE 2 STUDY (2017) Mcinnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL (2017) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution